Document:

Amdmt No. 1 to Amded and Restd Information dated March 6, 2004

 EXHIBIT 4.3 
  
 CORCEPT THERAPEUTICS INCORPORATED 
  
 AMENDMENT NO. 1 TO 
 AMENDED AND
RESTATED INFORMATION AND 
 REGISTRATION RIGHTS AGREEMENT 
  
 THIS AMENDMENT NO. 1 TO AMENDED AND RESTATED INFORMATION AND REGISTRATION RIGHTS AGREEMENT (the
“Amendment”) is made as of March 16, 2004 by and among Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”), and the persons and entities listed on the attached Exhibit A
(collectively, the “Investors”). 
  
 RECITALS 
  
 A. In connection with the sale by the
Company of its Series C Preferred Stock, the Company and the Investors entered into that certain Amended and Restated Information and Registration Rights Agreement dated as of May 8, 2001 (the “Rights Agreement”). 

 
 B. Section 18.5 of the Rights Agreement provides that the Rights Agreement
may be amended by a written instrument signed by the Company and by persons holding a majority of the Registrable Securities calculated on an as-converted basis. 
  
 C. The Investors who have executed this Amendment hold a majority of the Registrable Securities calculated on as-converted
basis. 
  
 D. In connection with the initial Registered public
offering of the Company’s Common Stock, the Investors and the Company wish to amend the Rights Agreement as set forth herein. 
  
 THE PARTIES AGREE AS FOLLOWS: 
  
 1. Terms not defined in this Amendment shall have the meaning set forth in the Rights Agreement. 
  
 2. Except as set forth in this Amendment, the Rights Agreement shall remain
in full force and effect. 
  
 3. Section 6.2(c) of the Rights
Agreement shall be amended and restated to read in its entirety as follows: 
  
 (c) Allocation of Shares in Piggyback Registration. In the event that the Underwriter’s Representative limits the number of shares to be included in a Registration pursuant to Section 6.2(b), the number of
shares to be included in such 
  

 Registration shall be allocated (subject to Section 6.2(b)) in the following manner: the number of shares
that may be included in the Registration and underwriting by selling stockholders shall be allocated among all Holders thereof and other holders of securities (other than Registrable Securities) requesting and legally entitled to include such
securities in such Registration, in proportion, as nearly as practicable, to the respective amounts of securities (including Registrable Securities) which such Holders and such other holders would otherwise be entitled to include in such
Registration; provided, however, that notwithstanding any provision to the contrary in this Agreement, including without limitation this Section 6, Alan Schatzberg, or a member of his immediate family (“Schatzberg”), may sell
in the Company’s initial Registered public offering up to Seven Hundred Fifty Thousand (750,000) shares of the Company’s Common Stock. In such event, provided that the Underwriter’s Representative advises the Company that no
Registrable Securities may be included in the initial Registered public offering due to market factors, then no Holder, other than Schatzberg, shall be entitled to exercise piggyback registration rights pursuant to this Agreement in connection with
such offering. No Registrable Securities or other securities excluded from the underwriting by reason of this Section 6.2(c) shall be included in the Registration Statement. 
  
 4. This Agreement may be executed in two or more counterparts, including by facsimile, each of which shall constitute an
original but all of which shall constitute one and the same instrument. 
  

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment to the Amended and Restated
Information and Registration Rights Agreement as of the date first above written. 
  

									
	 Company:
	 	 	 	 CORCEPT THERAPEUTICS INCORPORATED,
 a Delaware corporation

					
	 	 	 	 	 	 	By:	 	 /s/    ROBERT L. ROE

	 	 	 	 	 	 	 	 	

	 	 	 	 	 	 	 Name:
	 	 Robert L. Roe

	 	 	 	 	 	 	 	 	

	 	 	 	 	 	 	Title:	 	 President

	 	 	 	 	 	 	 	 	

  

									
	 Investor:
	 	 	 	 SUTTER HILL VENTURES,
 a California Limited Partnership

					
	 	 	 	 	 	 	By:	 	 /s/    G. LEONARD BAKER, JR.

	 	 	 	 	 	 	 	 	

	 	 	 	 	 	 	Name:	 	 G. Leonard Baker, Jr.

	 	 	 	 	 	 	 	 	

	 	 	 	 	 	 	 	 	Managing Director of the General Partner

  

									
	 	 	 	 	 SUTTER HILL ENTREPRENEURS FUND (AI), L.P. 

					
	 	 	 	 	 	 	By:	 	 /s/    G. LEONARD BAKER, JR.

	 	 	 	 	 	 	 	 	

	 	 	 	 	 	 	 Name:
	 	 G. Leonard Baker, Jr.

	 	 	 	 	 	 	 	 	

	 	 	 	 	 	 	 	 	Managing Director of the General Partner

  

									
	 	 	 	 	 SUTTER HILL ENTREPRENEURS FUND (QP), L.P. 

					
	 	 	 	 	 	 	By:	 	 /s/    G. LEONARD BAKER, JR.

	 	 	 	 	 	 	 	 	

	 	 	 	 	 	 	 Name:
	 	 G. Leonard Baker, Jr.

	 	 	 	 	 	 	 	 	

	 	 	 	 	 	 	 	 	Managing Director of the General Partner

  

			
	 TOW PARTNERS,
 A California Limited Partnership

		
	By:	 	 /s/    PAUL M. WYTHES

	 	 	

	 	 	Paul M. Wythes, General Partner

  

			
	ANVEST, L.P.
		
	By:	 	 /s/    DAVID L. ANDERSON

	 	 	

	 	 	David L. Anderson, General Partner

  

			
	SAUNDERS HOLDINGS, L.P.
		
	By:	 	 /s/    G. LEONARD BAKER, JR.

	 	 	

	 	 	G. Leonard Baker, Jr., General Partner

  

			
	 THE COXE/OTUS REVOCABLE TRUST
 U/A/D/ 4/23/98, TENCH COXE, TRUSTEE, 

		
	By:	 	 /s/    TENCH COXE

	 	 	

	 Name:
	 	 Tench Coxe

	 	 	

	Title:	 	 Trustee

	 	 	

  

			
	 THE TAMERLANE CHARITABLE REMAINDER UNITRUST

		
	By:	 	 /s/    TENCH COXE

	 	 	

	 	 	Tench Coxe, Trustee

  

			
	
	/s/    GREGORY P. SANDS
	

	GREGORY P. SANDS

  

			
	
	/s/    G. LEONARD BAKER, JR.
	

	G. LEONARD BAKER, JR.

  

			
	
	 GREGORY P. AND SARAH J.D. SANDS,
 TRUSTEES, THE GREGORY P. SAND SARAH J.D. SANDS TRUST AGREEMENT DATED 2/24/99
 /s/    GREGORY P. SANDS

	

	Gregory P. Sands, Trustee

  

			
	
	THE YOUNGER LIVING TRUST, U/A/D 1/20/95 WILLIAM H. YOUNGER, JR., TRUSTEE

			
	
	 /s/    WILLIAM H. YOUNGER, JR.

	

	William H. Younger, Jr., Trustee

  

			
	SHV M/P/T/ FBO MICHELE Y. PHUA, WELLS FARGO BANK, TRUSTEE
		
	 By:
	 	 /s/    EVAN HODGENS

	 	 	

	 Name:
	 	 Evan Hodgens

	 	 	

	 Title:
	 	 Vice President

	 	 	

  

			
	SHV M/P/T FBO WILLIAM H. YOUNGER, JR., WELLS FARGO BANK, TRUSTEE
		
	 By:
	 	 /s/    EVAN HODGENS

	 	 	

	 Name:
	 	 Evan Hodgens

	 	 	

	 Title:
	 	 Vice President

	 	 	

  

			
	S HV M/P/T FBO SHERRYL W. HOSSACK, WELLS FARGO BANK, TRUSTEE
		
	By:	 	 /s/    EVAN HODGENS

	 	 	

	 Name:
	 	 Evan Hodgens

	 	 	

	 Title:
	 	 Vice President

	 	 	

  

			
	WYTHES 1999 GRANDCHILDREN’S TRUST, JENNIFER W. VETTEL, PAUL M. WYTHES, JR., AND LINDA W. KNOLL, TRUSTEES
		
	By:	 	 /s/    DAVID E. SWEET

	 	 	

	 	 	David E. Sweet, under Power of Attorney

  

			
	THE REED TRAFFORD VETTEL 1999 IRREVOCABLE TRUST; LINDA W. KNOLL AND PAUL M. WYTHES, Jr., TRUSTEES
		
	By:	 	 /s/    DAVID E. SWEET

	 	 	

	 	 	Paul M. Wythes, Jr., Trustee by David E. Sweet under Power of Attorney

  

			
	PAUL M. WYTHES AND MARSHA R. WYTHES TRUSTEES, THE WYTHES LIVING TRUST (7/21/87)
		
	By:	 	 /s/    DAVID E. SWEET

	 	 	

	 	 	by David E. Sweet under Power of Attorney

  

			
	MARGARET LINDA VETTEL 1997 IRREVOCABLE TRUST, LINDA W. KNOLL AND PAUL M. WYTHES, JR., TRUSTEES
		
	By:	 	 /s/    DAVID E. SWEET

	 	 	

	 	 	 Paul M. Wythes, Jr., Trustee by David E. Sweet
 Under
Power of Attorney

  

			
	THE ANDERSON LIVING TRUST, U/A/D 1/22/98, DAVID L. ANDERSON, TRUSTEE
		
	By:	 	 /s/    DAVID L. ANDERSON

	 	 	

	 	 	David L. Anderson, Trustee

  

			
	
	 /s/    JAMES C. GAITHER

	

	JAMES C. GAITHER

  

			
	
	 /s/    LAWRENCE EBRINGER

	

	LAWRENCE EBRINGER

  

			
	JAMES N. WILSON AND PAMELA D. WILSON TRUST, U/D/T SEPTEMBER 27, 1983
		
	By:	 	 James N. Wilson

	 	 	

	 Name:
	 	James N. Wilson
	 Title:
	 	Trustee

  

			
	
	 /s/    PATRICIA TOM

	

	PATRICIA TOM

  

			
	
	 /s/    LYNNE M. BROWN

	

	LYNNE M. BROWN

  

			
	
	 /s/    MICHELE PHUA, TRUSTEE

	

	PHUA FAMILY TRUST DATED OCTOBER 24, 2002

  

			
	
	 /s/    DAVID E. SWEET

	

	SHERRYL W. HOSSACK by David E. Sweet Under Power of Attorney

  

			
	
	 /s/    DAVID E. SWEET

	

	DAVID SWEET

  

			
	1999 MELMON FAMILY TRUST, PAUL W. MELMON, TRUSTEE
		
	By:	 	 /s/    DAVID E. SWEET

	 	 	

	 Name:
	 	 David E. Sweet Under Power of Attorney

	 	 	

  

			
	WHITE FAMILY TRUST DATED 4/3/97, JAMES N. WHITE AND PATRICIA A. O’BRIEN, TRUSTEES
		
	 By:
	 	 /s/    JAMES N. WHITE

	 	 	

	 Name:
	 	 James N. White

	 	 	

	 Title:
	 	 Trustee

	 	 	

  

			
	ALTA BIOPHARMA PARTNERS II, L.P.
		
	 By:
	 	 /s/    ALIX MARDUEL

	 	 	

		
	 Name:
	 	 Alix Marduel

	 	 	

		
	 Title:
	 	 Managing Director

	 	 	

  

			
	ALTA EMBARCADERO BIOPHARMA PARTNERS II, LLC
		
	 By:
	 	 /s/    HILARY STRAIN

	 	 	

		
	 Name:
	 	 Hilary Strain

	 	 	

		
	 Title:
	 	 VP of Finance and Admin.

	 	 	

			
	MAVERICK FUND, LDC
		
	By:	 	 /s/    JOHN T. MCCAFFERTY

	 	 	

		
	 Name:
	 	 John T. McCafferty

	 	 	

		
	 Title:
	 	 Principal and General Counsel

	 	 	

  

			
	MAVERICK FUND USA, LTD.
		
	By:	 	 /s/    JOHN T. MCCAFFERTY

	 	 	

		
	 Name:
	 	 John T. McCafferty

	 	 	

		
	 Title:
	 	 Principal and General Counsel

	 	 	

  

			
	MAVERICK FUND II, LTD.
		
	By:	 	 /s/    JOHN T. MCCAFFERTY

	 	 	

		
	 Name:
	 	 John T. McCafferty

	 	 	

		
	 Title:
	 	 Principal and General Counsel

	 	 	

	
	  
 /s/    ROBERT
ROE

	

	ROBERT ROE

  

	
	  
 /s/    JAY
CECIL

	

	JAY CECIL

  
  

	
	  
 /s/    STUART
DUTY

	

	STUART DUTY

  

			
	  
 /s/    LAWRENCE J.
HATTERER

 DR. LAWRENCE HATTERER
  

	
	 /s/    JO SHEN

 JOSEPHINE HAI-I SHEN
  
  
 /s/    MALCOLM L. GEFTER

 MALCOLM L. GEFTER
  
  
 /s/    ANDREW GALLIGAN

 ANDREW GALLIGAN
  

			
	
	  
 /s/    VAUGHN D.
BRYSON

 VAUGHN D. BRYSON

	
	  
 /s/    STANLEY
WATSON

 STANLEY WATSON

  

			
	  
 /s/    SARAH A.
O’DOWD

 SARAH A. O’DOWD

	  
 /s/    CHRISTOPHER P.
SAARI

 CHRISTOPHER P. SAARI

	
	  
 /s/    ROBERT H.
ELLS

 ROBERT H. ELLS

	
	 

  

			
	  
 SHV M/P/T FBO MICHELE Y. PHUA, WELLS FARGO BANK,
TRUSTEE
  

		
	By:	 	 /s/    EVAN HODGENS

		
	 Name:
	 	 Evan Hodgens

		
	 Title:
	 	 Vice President

	
	  
 SHV PROFIT SHARING PLAN FBO GREGORY
 P. SANDS, WELLS FARGO BANK, TRUSTEE
  

		
	By:	 	 /s/    EVAN HODGENS

		
	 Name:
	 	 Evan Hodgens

		
	 Title:
	 	 Vice President

	
	  
 SHV PROFIT SHARING PLAN FBO DAVID E.
 SWEET (ROLLOVER), WELLS FARGO BANK, TRUSTEE
  

		
	By:	 	 /s/    EVAN HODGENS

		
	 Name:
	 	 Evan Hodgens

		
	 Title:
	 	  
 Vice President

  

			
	  
 SHV PROFIT SHARING PLAN FBO LYNNE
M.
 BROWN, WELLS FARGO BANK, TRUSTEE
  

		
	By:	 	 /s/    EVAN HODGENS

		
	 Name:
	 	 Evan Hodgens

		
	 Title:
	 	 Vice President

	
	  
 SHV PROFIT SHARING PLAN FBO
PATRICIA
 TOM, WELLS FARGO BANK, TRUSTEE
  

		
	By:	 	 /s/    EVAN HODGENS

		
	 Name:
	 	 Evan Hodgens

		
	 Title:
	 	 Vice PresidentResearch Agrmt dated February 12, 2002

 EXHIBIT 10.7 
  
 RESEARCH AGREEMENT/ cGMP MANUFACTURING 
  
 This agreement is entered into by and between KP Pharmaceutical Technology, Inc., 1212 Rappel Drive, Bloomington 47404 hereinafter called “Research
Organization”, and Corcept Therapeutics Incorporated a corporation with its principal office and place of business at 275 Middlefield Road, Suite A, Menlo Park, CA 94025, hereinafter called “Sponsor”. 
  
 WITNESSETH 
  
 WHEREAS, The research/development program contemplated by this Agreement is of mutual interest and benefit to the Research
Organization and to the Sponsor, 
  
 WHEREAS, a Proposal entitled: COST
ESTIMATE FOR DEVELOPMENT, MANUFACTURING AND TESTING OF C-1073 FILM COATED TABLETS (300 mg) FOR USE IN HUMANS attached hereto has been written which will guide the performance of this Agreement and the Research Organization agrees it is fully
able to perform the research program in a professional, competent manner with strict adherence to its terms, and the Research Organization will utilize its best efforts to do so, 
  
 WHEREAS, The Sponsor wishes to develop a tablet suitable for commercial sale with Research Organization and Research Organization
wishes to supply the tablets to Sponsor on commercially reasonable terms. 
  
 NOW THEREFORE, the parties hereto agree as follows: 
  

	1.	SCOPE OF WORK: The Research Organization shall exercise its best efforts to carry out the research set forth in the attached Proposal (“Research”) and Cost
Estimate (and terms). Project Number: KP02011R dated February 11, 2002 and consisting of pages 5 to 8. 

  

	2.	TERM OF AGREEMENT: This Agreement shall be effective for a period of 3 (three) years from the date of signing. The effective period may be extended by mutual written
agreement. Research Organization undertakes to manufacture tablets for Sponsor on commercially reasonable terms upon the regulatory approval of tablets manufactured by Research Organization. 

  

	3.	REGULATORY COMPLIANCE: The Research Organization will be responsible for the above entitled project to be developed, manufactured and tested in compliance with cGMP
regulations, all applicable local, state, and federal laws and regulations and in accordance with applicable Research Organization policies. The Research Organization shall retain all records resulting from the Research for 

 the time required by applicable federal regulations (the Sponsor will notify the Research Organization of
the FDA Application filing and approval status), and to allow for sponsor (or sponsor’s representative) and FDA inspection of all such records. 
  

	4.	RECORDKEEPING, REPORTING AND ACCESS: 

  
 4.1 The Sponsor’s authorized representative(s), and regulatory authorities to the extent required by law, may, during regular business hours, arrange
in advance with the Research Organization to: 
  
 (a) examine and
inspect the Research Organization’s facilities and operations required for performance of the Research; and 
  
 (b) inspect and copy all data and work products relating to the Research. 
  
 4.2 Research Organization shall cooperate with any regulatory authority and allow them access to applicable facilities,
records and data. 
  
 4.3 The Research Organization shall perform
the following record keeping and reporting obligations in a timely fashion: 
  
 (a) preparation and maintenance of complete, accurately written records, accounts, notes, reports and data of the Research; and 
  

(b) reports will be delivered to Sponsor by Research Organization in a timely manner throughout the performance of the research/development; and

  
 (c) a final written report (“Final Report”)
including a complete summary of research/development activity will be submitted to the Sponsor. 
  

	5.	OWNERSHIP OF MATERIALS AND INFORMATION: 

  
 5.1 All data, information, reports, any and all related documentation, all inventions, discoveries, formulae, procedures, any other intellectual property,
and any improvements thereto, whether patentable or not, which result or evolve as a result of the services performed hereunder by Research Organization for Sponsor (“Inventions”) shall be and remain the sole and exclusive property of
Sponsor if related to the materials provided to Research Organization by Sponsor. 
  
 5.2 Any Invention made, developed or discovered solely by Research Organization that constitutes an invention, improvement or other intellectual property relating to drug delivery technology, formulation, analysis or
manufacturing process of pharmaceutical products shall be and remain the property of Research Organization, and 
  

 2 

 Research Organization hereby grants to Sponsor a royalty free, exclusive license to develop, use, manufacture and sell
such invention in connection with the development, use manufacture and sale of the materials provided to Research Organization by Sponsor. 
  

	6.	INDEMNIFICATION: 

  
 6.1 Sponsor shall defend, indemnify and hold harmless the Research Organization its stockholders, directors, officers, employees and agents from any and
all liabilities, claims, actions or suits for (i) personal injury or death arising out of or in connection with the administration or use of the Research study drug(s) which are manufactured by Research Organization, (ii) negligence or willful
misconduct in advertising, labeling, or improper handling and storage by any person other than Research Organization, (iii) any specifications provided by Sponsor that are incorrect or do not meet FDA approved specifications, or other instructions
given by Sponsor in connection with any materials provided to Research Organization by Sponsor or Research Organization’s services provided hereunder, (iv) any misrepresentation by Sponsor or breach by Sponsor of any covenant or agreement
hereunder or (v) patent infringement relating to any materials provided to Research Organization by Sponsor or Research Organization’s services provided hereunder to the extent that such infringement does not arise as a result of a breach of
any representation or warranty of Research Organization hereunder, provided however: 
  
 (a) that such injuries or violations are not the result of Research Organization’s negligence or willful misconduct in performing the services hereunder, the violation of any applicable government law, rule or
regulation, or the breach of any covenant or agreement hereunder; 
  
 (b) that the Research Organization notifies the Sponsor immediately of the claim or lawsuit; 
  
 (c) that the Research Organization reasonably cooperates with the Sponsor in its investigation and defense thereof; and 
  
 (d) that the Research Organization not settle or otherwise compromise such
claim or lawsuit without the Sponsor’s prior written consent. 
  
 6.2 Deviations from the terms of the Proposal that may arise out of necessity will be considered compliance with the terms of the Proposal provided that Research Organization shall promptly notify Sponsor in writing of any such deviations,
and shall remedy such deviations to assure that the objectives of the proposal are met. 
  
 6.3 Sponsor agrees that it will maintain an insurance policy at levels sufficient to support the indemnification obligations assumed herein. Upon request the Sponsor will 
  

 3 

 provide evidence of its insurance and will provide to the Research Organization, thirty (30) days prior, written notice
of cancellation of its coverage. 
  
 6.4 Sponsor warrants that it
maintains a policy of insurance for product and general liability. Upon request by Research Organization, Sponsor shall provide evidence of its insurance and will provide to Sponsor thirty days prior written notice of any cancellation of its
coverage. 
  
 6.5 Research Organization shall defend, indemnify
and hold harmless the Sponsor its stockholders, directors, officers, employees and agents from any and all liabilities, claims, actions or suits for (i) any negligence or willful misconduct of Research Organization in performing the services
hereunder, (ii) any misrepresentation by Research Organization or breach by Research Organization of any covenant or agreement hereunder, or (iii) any claim asserted by a third party that Research Organization in performing the services hereunder
has infringed or misappropriated any proprietary or confidential information or intellectual property rights of such third party, except as relate to any materials, specifications or instructions provided to Research Organization by Sponsor.

  
 6.6 The indemnifying party shall provide a diligent defense
against any settlement of any claims brought or actions filed with respect to the subject of the indemnity contained herein, whether such claims or actions are rightfully or wrongfully brought or filed. The indemnified party shall not settle any
claims without the indemnifying party’s prior written consent, which consent may not be unreasonably withheld. 
  
 6.7 In no event shall either party be liable to the other for consequential or indirect damages, including without limitation lost profits or revenues.

  

	7.	TERMINATION: 

  
 7.1 This Agreement may be terminated by either party, upon immediate notice, if any of the following conditions occur: 
  
 (a) if the authorization and approval to perform the Research in the United
States is withdrawn by the U.S. Food and Drug Administration; or 
  
 (b) if either party fails to comply with any material term of the Agreement after receipt of written notice, with 30 day opportunity to cure, from the other party, 
  
 (c) the other party goes into bankruptcy or voluntary or involuntary dissolution, is declared insolvent, fails to pay its
debts as they come due, makes an assignment for the benefit of creditors, becomes subject to proceedings under any bankruptcy, composition, insolvency or similar law, 
  

 4 

 suffers the appointment of a receiver or trustee over all or substantially all of its assets or
properties, or otherwise ceases its business. 
  
 7.2 Upon the
effective date of termination and unless terminated for cause by Sponsor, there shall be an accounting conducted by the Research Organization, subject to verification by the Sponsor. Within thirty (30) days after receipt of adequate documentation
therefore, the Sponsor will make payment to the Research Organization for: 
  
 (a) all services properly rendered and moneys properly expended by the Research Organization until the date of termination not yet paid for; and 
  
 (b) reasonable non-cancelable obligations properly incurred for the Research by the Research Organization prior to the
effective date of termination; unless the Sponsor objects to any charge, in which case, the parties shall use best efforts to expeditiously resolve any disagreement. 
  
 7.3 Upon the effective date of termination and unless terminated for cause by Research Organization, the Research
Organization will credit or return to the Sponsor any funds not expended or obligated by the Research Organization in connection with the Research prior to the effective termination date of the notice of termination. 
  
 7.4 Immediately upon receipt of a notice of termination, the Research
Organization shall cease conducting research procedures related to proposal. 
  
 7.5 Termination of this Agreement by either party shall not affect the rights and obligations of the parties accrued prior to the effective date of the termination. 
  

	8.	DELIVERY OF UNUSED MATERIAL: Upon termination or completion of the Research, all unused compounds, drugs, equipment, whether or not completed, and other related
materials that were furnished to the Research Organization by or on behalf of the Sponsor shall be returned to the Sponsor at the Sponsor’s expense. 

  

	9.	ARBITRATION: All disputes between Research Organization and Sponsor arising from their dealings under this Agreement (either during or after the term of this
Agreement) shall be settled by binding Arbitration in the State of Delaware, under the rules of the American Arbitration Association. 

  

	10.	APPLICABLE LAW: This Agreement shall be governed by the laws of the state of Delaware. 

  

 5 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement in duplicate by proper persons thereunto duly
authorized. 
  

					
	 RESEARCH ORGANIZATION
 KP Pharmaceutical Technology, Inc.
 1212 Rappel Drive
 Bloomington, IN 47404
	 	 	 	 SPONSOR
 Corcept Therapeutics Incorporated
 275 Middlefield Road, Suite A,
 Menlo Park, CA 94025

			
	 /s/    R. S. Matharu        
	 	 	 	 /s/    Robert Roe      

	
	 	 	 	

			
	 Rajinder S. Matharu, Ph.D.
 President &
CEO
  
 02/11/02
	 	 	 	 Robert Roe, M.D
 President
  
 12 February, 2002

  

 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}]]